The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR1, compositions comprising such antibodies, and methods of use thereof.

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL12Rb2, compositions comprising such antibodies, and methods of use thereof.

Provided are oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of IFNAR1 RNA in a cell or animal, and in certain instances reducing the amount of IFNAR1 protein in a cell or animal. Such oligomeric compounds, methods, and pharmaceutical compositions are useful to treat diseases and conditions associated with neuroinflammation, including Aicardi-Goutières Syndrome, stroke, neuropsychiatric systemic lupus erythematosus, neuroinflammation following traumatic brain injury, neuro-autoimmune disorders, Alzheimer's disease, post-operative delirium and cognitive decline, cranial radiation-induced cognitive decline, viral infection-induced cognitive decline, neuromyelitis optica, and ataxia telangiectasia.

The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL27Rα, compositions comprising such antibodies, and methods of use thereof.

Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL28RA, compositions comprising such antibodies, and methods of use thereof.

Provided herein are IL12R binding molecules that bind to IL12Rb1 and IL12Rb2 and comprise an anti-IL12Rb2 sdAb and an anti-IL12Rb2 V.sub.HH antibody.

Provided herein are IL23 receptor binding molecules that bind to IL12Rβ1 and IL23R and comprise an anti-IL23R sdAb and an anti-IL23R V.sub.HH antibody.

Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 VHH antibody.

A soluble dimeric immunoadhesin includes a dimerized first polypeptide chain and a dimerized second polypeptide chain. The first polypeptide chain has a general formula of Z1-Z2, and the second polypeptide chain has a general formula of Y1-Y2. Z1 is (i) an extracellular domain of a first cell surface receptor or a functional variant or fragment thereof, or (ii) a first cytokine or a functional variant or fragment thereof; Z2 is a dimerization domain of an immunoglobulin constant region or a functional variant or fragment thereof. Y1 is an extracellular domain of a second cell surface receptor or a functional variant or fragment thereof, or (ii) a second cytokine or a functional variant or fragment thereof. Y2 is a dimerization domain of an immunoglobulin constant region or a functional variant or fragment thereof. A dimeric protein can be used for the treatment and prevention of infertility-related diseases.

he disclosure relates to the engineering of collagen-binding modification of masked therapeutic agents comprising one or more tumor-associated protease cleavage sites. Upon exposure to tumor-associated proteases in the tumor microenvironment, the polypeptide is cleaved, which unmasks the therapeutic agent, reducing off-target side effects and toxicity associated with systemic administration. Accordingly, aspects of the disclosure relate to a polypeptide comprising a therapeutic agent linked to a masking agent through a linker, wherein the linker comprises one or more tumor-associated protease cleavage sites, and wherein the masking agent blocks the association of the therapeutic agent to its therapeutic target, and further wherein the polypeptide is operatively linked to a collagen binding domain or a tumor-targeting agent.